Pharmacists in New Providence, New Jersey


12 Pharmacists found in New Providence
female pharmacist

Ariella Stefany Inzunza


Pharmacist
41 Spring St, New Providence, NJ 07974
201-380-7700    

female pharmacist

Brianna Leahy


Pharmacist
121 Chanlon Rd, New Providence, NJ 07974
973-224-9062    

female pharmacist

Dr. Erin Maggie Jones, PHARMD, MED, CSP


Pharmacist
121 Chanlon Rd, New Providence, NJ 07974
908-325-5736    



female pharmacist

Jacqulyne Inman, RPH, PHARMD


Pharmacist
41 Spring St Ste 105, New Providence, NJ 07974
201-380-7700    

female pharmacist

Jane Lew, RPH


Pharmacist
1260 Springfield Ave Ste 21, New Providence, NJ 07974
908-665-0001    

female pharmacist

Karla Mia Kristo, PHARMD


Pharmacist
121 Chanlon Rd, New Providence, NJ 07974
908-464-6816    

female pharmacist

Khushbu P Thaker, PHARM.D.


Pharmacist
121 Chanlon Rd Fl 2, New Providence, NJ 07974
908-977-9372     908-464-5275

female pharmacist

Lilian Tran


Pharmacist
1260 Springfield Ave, New Providence, NJ 07974
908-665-0001    

male pharmacist

Matthew David Roesch, RPH


Pharmacist
41 Spring St Ste 105, New Providence, NJ 07974
201-380-7700    

female pharmacist

Michelle Chan Cottino, PHARMD, BCACP


Pharmacist - Pharmacotherapy
121 Chanlon Rd Fl 2, New Providence, NJ 07974
908-219-6744    

female pharmacist

Mrs. Panagiota Kousoulis, RPH


Pharmacist - Clinician (PhC)/ Clinical Pharmacy Specialist
41 Spring St, New Providence, NJ 07974
732-692-2784     800-815-6808

male pharmacist

Zenas Wong, RPH


Pharmacist
1260 Springfield Ave, New Providence, NJ 07974
908-662-0001    


Type of Pharmacists:
Psychiatric Pharmacist: A licensed pharmacist who has demonstrated specialized knowledge and skill in optimizing care of patients with psychiatric illness by assessing and monitoring patients, recognizing drug-induced problems, and recommending appropriate treatment plans.
Oncology Pharmacist: A licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.